Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $48 to $26.
Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex
Mammoth Biosciences unveiled a nearly $700 million deal with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to develop in vivo gene therapies for…